Pharmaterials have a very strong link between materials characterisation and inhaled drug delivery formulation. Our methods for amorphous quantification are the basis of those adopted by Pharmacopoeias and are accepted by regulatory bodies.
The ability to predict and control the performance of an inhaled product is valuable in expediting the development of an active ingredient into a viable and reproducible formulation. However, due to the complexities of drug/carrier interactions and inevitable changes of particle integrity as a result of physical processing (such as micronisation), it is often very difficult to identify the specific paramaters that are causing the variability
With milligram levels of API and excipients we can provide detailed analytical assesment of the formulation, identifying and correcting the problems associated with such factors.
Types of analysis include:
- Particle size and shape distribution
- Surface morphology and physical form identification
- Spatially resolved surface chemistry & structural composition
- Changes in surface energies after processing
- Identification of component migration/segregation & contamination
Our services in characterisation and amorphous content determination are strengthened by our formulation development service for inhaled drug delivery.
Whether you are a mutli-national, SME, virtual or generic company we will be delighted to assist you in formulation development or dry powder inhalers and pressurized metered dose inhalers.
For our inhalation formulation service click here
For our Respisolv patented pMDI delivery system click here
To contact us to discuss inhalation and respiratory drug delivery click here